Globes [online] is reporting that BioView Ltd., a company from Israel, “has signed an agreement with the University of Texas MD Anderson Cancer Center, for the joint development of an early diagnosis system for lung cancer among high risk population groups.”
The company has expertise in designing and manufacturing pathology diagnostic system, dubbed BioView Duet™ scanning unit, developed to automatically scan for rare cells.
Here’s what the system can do:
BioView’s Duet™ system links the inspection of cell morphology and genetic content analysis of the cells, resulting in superior results that are unparalleled in speed, accuracy and sensitivity. Duet operates in fully automatic or interactive mode.
Scan 10 000 cells/minute in bright light illumination to:
Detect rare cells according to their morphology Classify cells by type Image samples stained with immuno-cytochemical stains
Scan thousands cells/hour in fluorescent illumination in true color and high resolution to:
Detect rare cells according to their fluorescent markers Identify genetic aberrations Enumerate the cells showing the genetic aberration of interest
Effectively analyze results:
Correlate results from both scans on one screen to view both morphological and genetic pictures Tag cells of interest for record and further analysis Sort cells by type, by marks applied by user or by number of spots in florescent mode in a given color Measure cell size and apply zoom function Examine captured image in a variety of color planes and define real translocation by analyzing color content of the image Store results in the system or transfer directly to patients’ files
Read more about the system, the proprietary software and preapration kits, over at the BioView…